has been cited by the following article(s):
|
[1]
|
Biochemical and molecular characterisation of the dyslipidaemia in Portugal
|
|
2018 |
|
|
|
|
[2]
|
The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method …
|
|
2017 |
|
|
|
|
[3]
|
The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study
|
|
2017 |
|
|
|
|
[4]
|
The new molecular entity evolocumab, one kind of PCSK9 inhibitor, reduce plasma small size LDL-cholesterol levels by using a new standardized method of …
|
|
2017 |
|
|
|
|
[5]
|
The Association Between Small Dense Low Density Lipoprotein and Coronary Artery Disease in North Indian Patients
|
|
Indian Journal of Clinical Biochemistry,
2016 |
|
|
|
|
[6]
|
Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in japanese patients with type 2 diabetes mellitus
|
|
Journal of Clinical & Translational Endocrinology,
2016 |
|
|
|
|
[7]
|
Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 …
|
|
Diabetes Research and Clinical Practice,
2016 |
|
|
|
|
[8]
|
Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus
|
|
Diabetes research and clinical practice,
2015 |
|
|
|
|
[9]
|
Status of Small Dense LDI in Cardiovascular Disease Subjects Taking Drug Therapy.
|
|
International Journal of Health Sciences and Research (IJHSR),
2015 |
|
|
|
|
[10]
|
Status of Small Dense LDL in Cardiovascular Disease Subjects Taking Drug Therapy
|
|
2015 |
|
|
|
|
[11]
|
Estimation of Small, Dense LDL Particles Using Equations Derived From Routine Lipid Parameters as Surrogate Markers. Biochem Anal Biochem 3: 146. doi …
|
|
2014 |
|
|
|
|
[12]
|
Rosuvastatin for lowering lipids
|
|
2014 |
|
|
|
|
[13]
|
Estimation of Small, Dense LDL Particles Using Equations Derived From Routine Lipid Parameters as Surrogate Markers
|
|
Biochemistry & Analytical Biochemistry,
2014 |
|
|
|
|
[14]
|
Lipid lowering efficacy of rosuvastatin
|
|
2012 |
|
|
|
|
[15]
|
LDL-C nhỏ, đậm đặc (sdLDL-C): một yếu tố dự đoán bệnh tim mạch mạnh hơn LDL-C
|
|
|
|
|
|
|
[1]
|
The Association Between Small Dense Low Density Lipoprotein and Coronary Artery Disease in North Indian Patients
Indian Journal of Clinical Biochemistry,
2017
DOI:10.1007/s12291-016-0592-7
|
|
|
|
|
[2]
|
The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size
Open Journal of Molecular and Integrative Physiology,
2017
DOI:10.4236/ojmip.2017.71001
|
|
|
|
|
[3]
|
Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus
Diabetes Research and Clinical Practice,
2016
DOI:10.1016/j.diabres.2015.10.013
|
|
|
|
|
[4]
|
Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus
Journal of Clinical & Translational Endocrinology,
2016
DOI:10.1016/j.jcte.2016.06.001
|
|
|
|
|
[5]
|
Rosuvastatin for lowering lipids
Cochrane Database of Systematic Reviews,
2014
DOI:10.1002/14651858.CD010254.pub2
|
|
|
|
|
[6]
|
Cochrane Database of Systematic Reviews
2014
DOI:10.1002/14651858.CD010254.pub2
|
|
|
|